Correlation Among Six Biologic Factors (p53, p21WAF1, MIB-1, EGFR, HER2, and Bcl-2) and Clinical Outcomes After Curative Chemoradiation Therapy in Squamous Cell Cervical Cancer

International Journal of Radiation Oncology Biology Physics

Volumn 74, Issue 4, 2009, Pages 1165-1172

  Yamashita, Hideomi ^a   Murakami, Naoya ^a   Asari, Takao ^a   Okuma, Kae ^a   Ohtomo, Kuni ^a   Nakagawa, Keiichi ^a  

^a UNIVERSITY OF TOKYO HOSPITAL   (Japan)

Author keywords

Biologic markers; Immunohistochemistry; Prognostic factors; Squamous cell carcinoma; Uterine cervix

Indexed keywords

BIOLOGIC MARKERS; IMMUNOHISTOCHEMISTRY; PROGNOSTIC FACTORS; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX;

BIOACTIVITY; GROWTH (MATERIALS); IMMUNOLOGY; MOLECULAR BIOLOGY; ONCOLOGY; PEPTIDES; TUMORS;

CORRELATION METHODS;

CISPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR 1; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; KI 67 ANTIGEN; PROTEIN BCL 2; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CORRELATION ANALYSIS; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME; UTERINE CERVIX CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CELL CYCLE PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; FEMALE; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53; UTERINE CERVICAL NEOPLASMS;

EID: 67649556464     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2008.09.005     Document Type: Article

References (47)

1. Suzuki Y., Nakano T., Arai T., Morita S., Tsujii H., and Oka K. Progesterone receptor is a favorable prognostic factor of radiation therapy for adenocarcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys 47 (2000) 1229-1234
2. Tsuda H., Jiko K., Tsugane S., Yajima M., Yamada T., Tanemura K., Tsunematsu R., Ohmi K., Sonoda T., and Hirohashi S. Prognostic value of p53 protein accumulation in cancer cell nuclei in adenocarcinoma of the uterine cervix. Jpn J Cancer Res 86 (1995) 1049-1053
3. Kihana T., Tsuda H., Teshima S., Nomoto K., Tsugane S., Sonoda T., Matsuura S., and Hirohashi S. Prognostic significance of the overexpression of c-erbB2 protein in adenocarcinoma of the cervix. Cancer 73 (1994) 148-153
4. Lu X., Toki T., Konishi I., Nikaido T., and Fujii S. Expression of p21WAF1/Cip1 in adenocarcinoma of the uterine cervix. Cancer 82 (1998) 2409-2417
5. International Federation of Gynecology and Obstetrics. Annual report on the results of treatment in carcinoma of the uterus, vagina and ovary, vol. 16 (1979), FIGO, Radiumhemmet, Sweden
6. Poulsen H.E., Taylor C.W., and Sobin L.H. Histological typing of female genital tract tumors, No. 13 (1975), World Health Organization, Geneva, Switzerland
7. Yamashita H., Nakagawa K., Tago M., et al. Comparison between conventional surgery and radiotherapy for FIGO Stage I-II cervical carcinoma: A retrospective Japanese study. Gynecol Oncol 97 (2005) 834-839
8. Yamashita H., Nakagawa K., Tago M., et al. Treatment results and prognostic analysis of radical radiotherapy for locally advanced cancer of the uterine cervix. Br J Radiol 78 (2005) 821-826
9. Yamashita H., Nakagawa K., Tago M., et al. Small bowel perforation without tumor recurrence after radiotherapy for cervical carcinoma: Report of seven cases. J Obstet Gynaecol Res 32 (2006) 235-242
10. El-Deiry W.S., Harper J.W., O'Connor P.M., et al. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 54 (1994) 1169-1174
11. Lane D.P. A death in the life of p53. Nature 362 (1993) 786-787
12. Jain D., Srinivasan R., Patel F.D., and Kumari Gupta S. Evaluation of p53 and Bcl-2 expression as prognostic markers in invasive cervical carcinoma Stage IIb/III patients treated by radiotherapy. Gynecol Oncol 88 (2003) 22-28
13. Oka K., Suzuki Y., and Nakano T. p27 and p53 Expression in cervical squamous cell carcinoma patients treated with radiation therapy alone: Radiotherapeutic effect and prognosis. Cancer 88 (2000) 2766-2773
14. Xiong Y., Hannon G.J., Zhang H., et al. p21 Is a universal inhibitor of cyclin kinase. Nature 366 (1993) 701-704
15. Niibe Y., Nakano T., Ohno T., et al. Relationship between p21/WAF-1/CIP-1 and apoptosis in cervical cancer during radiation therapy. Int J Radiat Oncol Biol Phys 44 (1999) 297-303
16. Gerdes J., Lemke H., Basich H., et al. Cell cycle analysis of a cell proliferation associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 133 (1984) 1710-1715
17. Brown D.C., Cole D., Gatter K.C., and Mason D.Y. Carcinoma of the cervix uteri: An assessment of tumour proliferation using the monoclonal antibody Ki67. Br J Cancer 57 (1988) 178-181
18. Avall-Lundqvist E.H., Silfversward C., Aspenblad U., et al. The impact of tumour angiogenesis, p53 overexpression and proliferative activity (MIB-1) on survival in squamous cervical carcinoma. Eur J Cancer 33 (1997) 1799-1804
19. Bar J.K., Harlozinska A., Markowska J., and Nowak M. Studies on tumor proliferation using monoclonal antibody, Ki 67 and expression of p53 in cancer of the uterine cervix. Eur J Gynaecol Oncol 17 (1996) 378-380
20. Cole D.J., Brown D.C., Crossley E., et al. Carcinoma of the cervix uteri: An assessment of the relationship of tumour proliferation to prognosis. Br J Cancer 65 (1992) 783-785
21. Dellas A., Schultheiss E., Almendral A.C., et al. Altered expression of mdm-2 and its association with p53 protein status, tumor-cell-proliferation rate and prognosis in cervical neoplasia. Int J Cancer 74 (1997) 421-425
22. Garzetti G.G., Ciavattini A., Lucarini G., et al. MIB 1 immunostaining in Stage I squamous cervical carcinoma: Relationship with natural killer cell activity. Gynecol Oncol 58 (1995) 28-33
23. Garzetti G.G., Ciavattini A., Lucarini G., et al. MIB 1 immunostaining in cervical carcinoma of young patients. Gynecol Oncol 67 (1997) 184-187
24. Nakano T., and Oka K. Differential value of Ki-67 index and mitotic index of proliferating cell population. An assessment of cell cycle and prognosis in radiation therapy for cervical cancer. Cancer 72 (1993) 2401-2408
25. Oka K., Nakano T., and Arai T. Expression of proliferation-associated antigens in cervical carcinoma: Correlations among indexes. Pathol Res Pract 191 (1995) 997-1003
26. Wong W.S., and McGuire L.J. Tumor growth fraction in cervical carcinoma. Gynecol Oncol 40 (1991) 48-54
27. Wong F.W. Immunohistochemical detection of proliferating tumor cells in cervical cancer using monoclonal antibody Ki-67. Gynecol Obstet Invest 37 (1994) 123-126
28. Tjalma W., Weyler J., Goovaerts G., et al. Prognostic value of bcl-2 expression in patients with operable carcinoma of the uterine cervix. J Clin Pathol 50 (1997) 33-36
29. Adams J.M., and Cory S. The Bcl-2 protein family: Arbiters of cell survival. Science 281 (1998) 1322-1326
30. Tjalma W., De Cuyper E., Weyler J., et al. Expression of bcl-2 in invasive and in situ carcinoma of the uterine cervix. Am J Obstet Gynecol 178 (1998) 113-117
31. Oltvai Z.N., Milliman C.L., and Korsmeyer S.J. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74 (1993) 609-619
32. Kim J.W., Kim Y.T., Kim D.K., et al. Expression of epidermal growth factor receptor in carcinoma of the cervix. Gynecol Oncol 60 (1996) 283-287
33. Kedzia W., Schmidt M., Frankowski A., and Spaczyński M. Immunohistochemical assay of p53, cyclin D1, c-erbB2, EGFr and Ki-67 proteins in HPV-positive and HPV-negative cervical cancers. Folia Histochem Cytobiol 40 (2002) 37-41
34. Oh M.J., Choi J.H., Kim I.H., et al. Detection of epidermal growth factor receptor in the serum of patients with cervical carcinoma. Clin Cancer Res 6 (2000) 4760-4763
35. Kersemaekers A.M., Fleuren G.J., Kenter G.G., et al. Oncogene alterations in carcinomas of the uterine cervix: Overexpression of the epidermal growth factor receptor is associated with poor prognosis. Clin Cancer Res 5 (1999) 577-586
36. Mitra A.B., Murty V.V., Pratap M., et al. ERBB2 (HER2/neu) oncogene is frequently amplified in squamous cell carcinoma of the uterine cervix. Cancer Res 54 (1994) 637-639
37. Kihana T., Tsuda H., Teshima S., et al. Prognostic significance of the overexpression of c-erbB-2 protein in adenocarcinoma of the uterine cervix. Cancer 73 (1994) 148-153
38. Hale R.J., Buckley C.H., Gullick W.J., et al. Prognostic value of epidermal growth factor receptor expression in cervical carcinoma. J Clin Pathol 46 (1993) 149-153
39. Pfeiffer D., Stellwag B., Pfeiffer A., et al. Clinical implications of the epidermal growth factor receptor in the squamous cell carcinoma of the uterine cervix. Gynecol Oncol 33 (1989) 146-150
40. Leung T.W., Cheung A.N., Cheng D.K., et al. Expressions of c-erbB-2, epidermal growth factor receptor and pan-ras proto-oncogenes in adenocarcinoma of the cervix: Correlation with clinical prognosis. Oncol Rep 8 (2001) 1159-1164
41. Ngan H.Y., Cheung A.N., Liu S.S., et al. Abnormal expression of epidermal growth factor receptor and c-erbB2 in squamous cell carcinoma of the cervix: Correlation with human papillomavirus and prognosis. Tumour Biol 22 (2001) 176-183
42. Scambia G., Ferrandina G., Distefano M., et al. Epidermal growth factor receptor (EGFR) is not related to the prognosis of cervical cancer. Cancer Lett 123 (1998) 135-139
43. Kristensen G.B., Holm R., Abeler V.M., and Tropé C.G. Evaluation of the prognostic significance of cathepsin D, epidermal growth factor receptor, and c-erbB-2 in early cervical squamous cell carcinoma. An immunohistochemical study. Cancer 78 (1996) 433-440
44. Lee C.M., Shrieve D.C., Zempolich K.A., et al. Correlation between human epidermal growth factor receptor family (EGFR, HER2, HER3, HER4), phosphorylated Akt (P-Akt), and clinical outcomes after radiation therapy in carcinoma of the cervix. Gynecol Oncol 99 (2005) 415-421
45. Wang Z., Xu B., Lin D., et al. XRCC1 polymorphisms and severe toxicity in lung cancer patients treated with cisplatin-based chemotherapy in Chinese population. Lung Cancer 62 (2008) 99-104
46. Quintela-Fandino M., Hitt R., Medina P.P., et al. DNA-repair gene polymorphisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatin-based induction chemotherapy. J Clin Oncol 24 (2006) 4333-4339
47. Chung H.H., Kim M.K., Kim J.W., et al. XRCC1 R399Q polymorphism is associated with response to platinum-based neoadjuvant chemotherapy in bulky cervical cancer. Gynecol Oncol 103 (2006) 1031-1037